Recent Updates
Recently added Catalysts

Aligos Therapeutics, Inc.

ALGS
Richly ValuedBiotech · Clinical
FDA catalysts, PDUFA dates & pipeline intelligence
$5.31
▼ -0.01 · -0.19%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full ALGS financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $3.9852W HIGH $13.69
Volume
37.37 K
Value Traded
4.44 M
Short % Float
14.39%
-4.15%Week
-3.45%1 Month
-19.79%3 Month
-33.58%6 Month
-99.1%5 Year
-98.68%All Time

Cash Data

Unlock ALGS cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
33.16 M
EPS (TTM)
-12.16
P/E Ratio
-
Ent. Value
2.78 M
Total Shares
6.24 M
Float Shares
4.85 M
Insiders
22.29%
Institutions
36.71%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Pre-clinical data presentation
ALG-215007
Hepatitis Delta Virus
Pre-clinicalRNA-Based TherapiesInfectious Diseases
Unlock every ALGS catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

ALGS Catalyst Timeline

Dated clinical, regulatory and corporate events for Aligos Therapeutics, Inc.

Catalyst Timeline

Dated clinical, regulatory & corporate events for Aligos Therapeutics, Inc.

480Total events
15Upcoming
69Tier-1 (high impact)
2019 to 2028Coverage

Upcoming catalysts 2

T2Quarterly Update
Subscribe to view catalyst details
T2Runway Guidance Update
Subscribe to view catalyst details

Event history 50

●AbstractPresentation
Five abstracts accepted for presentation at The Liver Meeting 2026 released on AASLD website
source ↗
◆Topline ReadoutALG-055009Clinical Data
Topline data from HERALD phase 2a trial
metabolic dysfunction-associated steatohepatitissource ↗
▲First Patient DosedALG-170675Trial
First participant dosed in Phase 1 study of ALG-170675 in China
chronic hepatitis B virus (HBV) infectionsource ↗
●Quarterly UpdateCorporate
Q2 2026 financial results reported
source ↗
▲Breakthrough Therapy DesignationPevifoscorvirDesignation
Breakthrough Therapy Designation granted by CDE of China's NMPA for pevifoscorvir sodium
chronic hepatitis B virus (HBV) infectionsource ↗
▲Enrollment CompletePevifoscorvirTrial
Completed enrollment in Phase 2 B-SUPREME study
chronic hepatitis B virus (HBV) infectionsource ↗
▲IND ClearanceALG-170675IND
IND approval in China for ALG-170675
chronic hepatitis B virus (HBV) infectionsource ↗
●Runway Guidance UpdateCorporate
Cash runway guidance through Q4 2026
source ↗
▲Partnership / LicensePevifoscorvirCorporate
Exclusive license deal with Amoytop for Greater China
chronic hepatitis B virus (HBV) infectionsource ↗
◆Trial InitiationALG-170675Trial
Phase 1 SAD/MAD study expected to start in China
chronic hepatitis B virus (HBV) infectionsource ↗
Unlock the full ALGS catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How ALGS actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
2026-05-28ALG-093940 Pre-clinical data readout Pre-clinical
Unlock 10 more ALGS historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

D29 / 100
Pipeline Score
$3M
Pipeline Value
Richly Valued
Valuation Signal
4
Drugs Scored
0.1x
rNPV / MCap
Top 70%
Micro Cap
(rank 461 of 658)
Percentile Rank
Aligos Therapeutics, Inc. faces pipeline headwinds (29/100), with $373M risk-adjusted pipeline value, led by ALG-055009 in NASH (Phase 2), but cash runway is a concern.
Showing 1 of 4 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
ALG-055009 Small moleculeCompletedNCT06342947NASHPhase 2 COMPLETED 102Sep 9, 2024
Unlock the ALGS pipeline intelligence model
Every scored asset with PTRS, rNPV, enrollment velocity and trial design quality.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every ALGS program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
pevifoscorvir sodium
BreakthroughFast Track
chronic HBV infectionPhase 12026-05-2740% of HBeAg+ participants achieved significant reductions in HBsAg; 4 (44%) maintained HBV DNA levels below the lower limit of quantification (LLOQ; 10 IU/mL); 40% (4/10) achieved HBsAg <3,000 IU/mL at 48 weeksRead MoreAligos Therapeutics Presents Positive Data at the EASL Congress 2026Read More
Scroll for more · summaries link to the source press release
Unlock every ALGS trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock ALGS insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
Preston HeatherDirectorGrant/Award 5,860 5,860 held$0.00 06/25/2026
Unlock the full ALGS insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Hedge Funds invested in ALGS

Fund % of Portfolio Current MV Shares Owned Activity
Deep Track Capital, LP 0 % (-100 %) 2.56 M 444.11 K
Unlock every fund holding ALGS
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in ALGS
Shares held by hedge funds each quarter, and who bought or sold.

ALGS Institutional Ownership Trends

Options Data

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
Unlock ALGS option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live ALGS option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock ALGS options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How ALGS ranks across every disease it competes in

Competitive Position is a premium feature
See how ALGS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

ALGS News

ALGS
Oct 5, 2026
ALGSConferences/Events
▼ -0.2%today

Aligos Therapeutics Announces Five Abstracts Accepted for Presentation at The Liver Meeting® 2026

Aligos Therapeutics announced that five abstracts have been accepted for presentation at The Liver Meeting® 2026, scheduled for November 5-9 in Denver, CO. The abstracts highlight the company's innovative therapies targeting chronic hepatitis B virus infection, showcasing promising results from their clinical research. This participation underscores Aligos's commitment to advancing treatment options in liver diseases.

Read more →
ALGS
Sep 2, 2026
ALGSConferences/Events

Aligos Therapeutics to Present at the Cantor Global Healthcare Conference

Aligos Therapeutics, a clinical-stage biopharmaceutical company, will present at the Cantor Global Healthcare Conference on September 9, 2026. The presentation will focus on their pipeline aimed at treating liver and viral diseases. A replay will be available for 30 days post-event, emphasizing their commitment to improving patient outcomes.

Read more →
ALGS
Aug 12, 2026
ALGSPhases

Aligos Therapeutics Announces First Participant Dosed in the Phase 1 Study of its Potentially Best-in-Class Antisense Oligonucleotide ALG-170675 by its Partner Amoytop in China

Aligos Therapeutics has initiated dosing in a Phase 1 study for ALG-170675, an antisense oligonucleotide aimed at treating chronic hepatitis B virus infection. Conducted by Amoytop in China, the study will assess safety, tolerability, and pharmacokinetics. The first participant has been dosed, marking a significant milestone for Aligos in advancing therapies for chronic HBV.

Read more →
ALGS
Aug 6, 2026
ALGSGeneral
▲ +16.2%on this news· ran to +54% by day 3

Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results

Aligos Therapeutics reported significant progress in its business and financial results for Q2 2026. The company secured a $25 million upfront payment from a licensing agreement and completed enrollment for its Phase 2 B-SUPREME study. Additionally, Aligos received Breakthrough Designation for its drug in China, with topline data expected in late Q3 2027. However, the company also reported a net loss of $1.5 million during the quarter.

Read more →
ALGS
Jul 30, 2026
ALGSGeneral

Aligos Therapeutics to Announce 2nd Quarter 2026 Financial Results on August 6, 2026

Aligos Therapeutics, a clinical stage biotechnology company, will announce its second quarter 2026 financial results on August 6, 2026, before U.S. markets open. The company aims to enhance patient outcomes through innovative therapies for liver and viral diseases. Aligos emphasizes its commitment to addressing high unmet medical needs in chronic hepatitis B virus infection.

Read more →
ALGS
Jul 13, 2026
ALGSPhases

Aligos Therapeutics Announces the Completion of Enrollment in the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium Under Development for the Treatment of Chronic HBV Infection

Aligos Therapeutics has announced the completion of enrollment in its Phase 2 B-SUPREME study for pevifoscorvir sodium, targeting chronic HBV infection. The study enrolled 131 HBeAg+ and 114 HBeAg- participants, surpassing initial enrollment goals. Topline data is anticipated in late Q3 2027, marking a crucial step in the development of this potential treatment.

Read more →
ALGS
Jul 6, 2026
ALGSGeneral

Aligos Therapeutics Receives Upfront Payment of $25M USD from the Exclusive License Deal of Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection

Aligos Therapeutics has secured a $25 million upfront payment from Xiamen Amoytop Biotech for the exclusive licensing of pevifoscorvir sodium in Greater China. The drug has also received Breakthrough Therapy Designation from China's regulatory authority, facilitating priority review for its New Drug Application. Aligos stands to gain up to $420 million in milestone payments and retains rights in other key markets.

Read more →
ALGS
May 27, 2026
ALGSConferences/Events

Aligos Therapeutics Presents Positive Data at the EASL Congress 2026

Aligos Therapeutics presented promising data at the EASL Congress 2026, highlighting the efficacy of pevifoscorvir sodium in reducing the cccDNA reservoir in chronic HBV patients. Notably, 40% of participants achieved significant reductions in HBsAg, suggesting eligibility for functional cure treatments. The combination of pevifoscorvir sodium and antisense oligonucleotide ALG-170675 showed synergistic effects, indicating a potential shift in treatment standards for chronic HBV infection.

Read more →
ALGS
May 13, 2026
ALGSConferences/Events

Aligos Therapeutics Announces Ten Abstracts Accepted for Presentation at the EASL Congress 2026

Aligos Therapeutics has announced that ten of its abstracts have been accepted for poster presentations at the EASL Congress 2026 in Barcelona. The presentations will focus on their innovative therapies targeting chronic hepatitis B and metabolic dysfunction-associated steatohepatitis. This recognition highlights Aligos' commitment to advancing treatment options in liver diseases.

Read more →
ALGS
May 7, 2026
ALGSPhases
▼ -5.3%on this news

Aligos Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results

Aligos Therapeutics has reported its business progress and financial results for Q1 2026, highlighting the Fast Track Designation for its drug, pevifoscorvir sodium, aimed at chronic HBV infection. The interim analysis of the B-SUPREME study indicated positive results, with a recommendation to increase participant numbers to improve the study's success rate. However, the company also reported a significant net loss compared to the previous year due to rising R&D expenditures. Aligos continues to collaborate with Amoytop for developments in Greater China, which could enhance its market presence.

Read more →
ALGS
Apr 30, 2026
ALGSGeneral

Aligos Therapeutics to Announce 1st Quarter 2026 Financial Results on May 7, 2026

Aligos Therapeutics, Inc. has announced it will report its first quarter 2026 financial results on May 7, 2026. The company is focused on improving patient outcomes through its development of best-in-class therapies aimed at liver and viral diseases, addressing conditions like chronic hepatitis B and metabolic disorders. However, the press release also emphasizes the inherent risks associated with drug development and clinical trials, which may affect actual results compared to forward-looking statements. Investors are advised to refer to Aligos' annual report for detailed risks.

Read more →
ALGS
Apr 24, 2026
ALGSGeneral

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aligos Therapeutics, Inc. has announced the granting of stock options amounting to 10,700 shares to newly hired employees as part of an Inducement Grant under Nasdaq Listing Rule 5635(c)(4). This move aims to attract talent as the company focuses on developing therapies for liver and viral diseases. The stock options will vest over four years, reflecting a commitment to employee retention and growth in the clinical stage biopharmaceutical field. However, the announcement includes forward-looking statements that highlight potential risks and uncertainties related to drug development and regulatory processes.

Read more →
ALGS
Apr 16, 2026
ALGSGeneral

Aligos Therapeutics Enters into Exclusive License Deal with Xiamen Amoytop Biotech Co., Ltd. to Develop and Commercialize Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection

Aligos Therapeutics has entered an exclusive licensing agreement with Xiamen Amoytop Biotech to develop and commercialize pevifoscorvir sodium for chronic hepatitis B in Greater China. Aligos will receive an upfront payment of $25 million and could earn up to $420 million in milestones. The partnership aims to leverage Amoytop's established market presence to enhance the drug's development and regulatory success.

Read more →
ALGS
Apr 15, 2026
ALGSPhases
▼ -15.1%on this news· ran to -26% by day 3shared move

Aligos Therapeutics Announces First Interim Analysis Results from the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium in Participants with Chronic Hepatitis B Virus Infection and Grant of FDA Fast Track Designation

Aligos Therapeutics announced positive interim results from the Phase 2 B-SUPREME study of pevifoscorvir sodium for chronic hepatitis B virus infection. The independent Data Safety Monitoring Board recommended increasing the sample size for better statistical power. Additionally, the FDA granted Fast Track Designation to the drug, facilitating its development and review process.

Read more →
ALGS
Mar 5, 2026
ALGSPhases

Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2025 Financial Results

Aligos Therapeutics reported progress in its clinical trials and financial results for 2025. The Phase 2 B-SUPREME study of pevifoscorvir sodium has completed enrollment for the HBeAg- cohort, with ongoing enrollment for HBeAg+ participants. The company also advanced ALG-170675 into IND-enabling studies and appointed James Hassard as Chief Commercial Officer. Financially, Aligos showed reduced net losses compared to 2024.

Read more →
ALGS
Feb 26, 2026
ALGSGeneral
▲ +8.1%on this news

Aligos Therapeutics to Announce 4th Quarter 2025 Financial Results on March 5, 2026

Aligos Therapeutics, a clinical-stage biotechnology company, will announce its fourth quarter 2025 financial results on March 5, 2026. The company aims to improve patient outcomes through innovative therapies for liver and viral diseases. Aligos has a pipeline targeting chronic hepatitis B, metabolic dysfunction-associated steatohepatitis, obesity, and coronaviruses.

Read more →
ALGS
Feb 23, 2026
ALGSConferences/Events

Aligos Therapeutics Presents Positive Data at the Conference on Retroviruses and Opportunistic Infections (CROI)

Aligos Therapeutics presented promising data at the Conference on Retroviruses and Opportunistic Infections (CROI), focusing on two key projects. The Phase 1 study of pevifoscorvir sodium demonstrated high viral suppression in chronic hepatitis B virus (HBV) patients. Additionally, data on ALG-097558, a pan-coronavirus protease inhibitor, was showcased, highlighting its pharmacokinetics in patients with renal and hepatic impairment.

Read more →
ALGS
Jan 21, 2026
ALGSPhases

Aligos Therapeutics Provides Phase 2 B-SUPREME Study Progress Updates

Aligos Therapeutics has provided an update on its Phase 2 B-SUPREME study for pevifoscorvir sodium in chronic hepatitis B patients. Currently, 144 subjects are enrolled, with interim analyses planned for 2026. The company remains optimistic about the drug's potential, with topline data expected in 2027. However, a leadership change has occurred with the resignation of the Chief Medical Officer.

Read more →

About Aligos Therapeutics, Inc.

South San Francisco, CA 82 employees aligos.com
HeadquartersONE CORPORATE DR., 2ND FLOOR, SOUTH SAN FRANCISCO, CA, 94080
Founded2018
BIOPHARMAWATCH ELITE PLUS
Trade the next ALGS catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime